Simplex Trading
BBIO icon

Simplex Trading’s BridgeBio Pharma BBIO Stock Holding History

Simplex Trading’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.68M Sell
36,100
-89,600
-71% -$6.49M ﹤0.01% 1575
2025
Q4 		$9.61M Sell
125,700
-78,800
-39% -$5.17M 0.01% 869
2025
Q3 		$10.6M Sell
204,500
-86,500
-30% -$4.22M 0.01% 930
2025
Q2 		$12.6M Sell
291,000
-15,300
-5% -$556K 0.01% 755
2025
Q1 		$10.6M Sell
306,300
-71,500
-19% -$2.41M 0.01% 857
2024
Q4 		$10.4M Buy
377,800
+136,900
+57% +$3.54M 0.01% 1007
2024
Q3 		$6.13M Sell
240,900
-1,500
-0.6% -$39.4K ﹤0.01% 1349
2024
Q2 		$6.14M Buy
242,400
+35,400
+17% +$968K ﹤0.01% 1305
2024
Q1 		$6.4M Buy
207,000
+58,200
+39% +$1.98M ﹤0.01% 1418
2023
Q4 		$6.01M Sell
148,800
-155,800
-51% -$4.68M ﹤0.01% 1418
2023
Q3 		$8.03M Sell
304,600
-36,200
-11% -$1.03M 0.01% 1035
2023
Q2 		$5.86M Buy
340,800
+115,400
+51% +$1.74M ﹤0.01% 1213
2023
Q1 		$3.74M Buy
225,400
+146,200
+185% +$1.7M ﹤0.01% 1485
2022
Q4 		$603K Buy
79,200
+44,800
+130% +$429K ﹤0.01% 2981
2022
Q3 		$341K Sell
34,400
-55,300
-62% -$575K ﹤0.01% 3920
2022
Q2 		$814K Sell
89,700
-35,500
-28% -$297K ﹤0.01% 2852
2022
Q1 		$1.27M Sell
125,200
-80,400
-39% -$825K ﹤0.01% 2616
2021
Q4 		$3.43M Buy
205,600
+205,400
+102,700% +$8.69M ﹤0.01% 1525
2021
Q3 		$12K Buy
200
+100
+100% +$5.36K ﹤0.01% 8801
2021
Q2 		$6K Buy
100
+90
+900% +$5.14K ﹤0.01% 9352
2021
Q1 		$61K Sell
10
-136
-93% -$8.9K ﹤0.01% 6358
2020
Q4 		$1.04M Buy
+146
New +$7.04K ﹤0.01% 2514
2020
Q3 		– Sell
-480
Closed -$1.56M – 7777
2020
Q2 		$1.56M Buy
480
+442
+1,163% +$13.5K ﹤0.01% 1730
2020
Q1 		$110K Buy
+38
New +$1.18K ﹤0.01% 4267

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Simplex Trading's BBIO Position: Q1 2026 in Review

Simplex Trading increased its BridgeBio Pharma (BBIO) stake by 125% in Q1 2026, buying an estimated $1.67M and bringing the position to 41,434 shares worth $3.08M. The position accounts for ﹤0.01% of the portfolio, ranked #1479.

Simplex Trading first reported a position in BBIO in Q1 2020 and has held it in 12 quarters since. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Simplex Trading held 41,434 shares of BridgeBio Pharma worth $3.08M as of Q1 2026.
  • Simplex Trading bought 23,022 BridgeBio Pharma shares in Q1 2026, an estimated $1.67M.
  • BridgeBio Pharma made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #1479 holding.
  • Simplex Trading first reported a position in BridgeBio Pharma in Q1 2020 and has held it in 12 quarters since.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.